LifeMD’s (LFMD) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of LifeMD (NASDAQ:LFMD) in a report released on Monday morning,Benzinga reports. HC Wainwright currently has a $12.00 target price on the stock.

A number of other equities research analysts also recently issued reports on the stock. B. Riley began coverage on shares of LifeMD in a research report on Friday, August 23rd. They issued a “buy” rating and a $11.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $15.00 target price on shares of LifeMD in a research note on Friday, September 20th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $12.00.

LifeMD Trading Down 14.6 %

Shares of NASDAQ LFMD opened at $5.97 on Monday. LifeMD has a fifty-two week low of $3.99 and a fifty-two week high of $12.88. The company has a quick ratio of 0.78, a current ratio of 0.83 and a debt-to-equity ratio of 10.83. The firm’s 50-day simple moving average is $4.97 and its 200 day simple moving average is $6.46.

Institutional Trading of LifeMD

A number of large investors have recently modified their holdings of LFMD. Quest Partners LLC bought a new stake in LifeMD during the second quarter worth about $31,000. EntryPoint Capital LLC purchased a new position in shares of LifeMD during the first quarter valued at approximately $89,000. nVerses Capital LLC bought a new position in LifeMD in the 3rd quarter worth $46,000. Intech Investment Management LLC bought a new stake in LifeMD during the 3rd quarter valued at approximately $54,000. Finally, CWM LLC bought a new position in LifeMD in the third quarter worth $59,000. Institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.